Grosclaude P, Colonna M, Hedelin G, Tretarre B, Arveux P, Lesec'h J M, Raverdy N, Sauvage-Machelard M
Registre des Cancers du Tarn, Chemin des Trois Tarn, Albi, France.
Breast Cancer Res Treat. 2001 Nov;70(2):137-43. doi: 10.1023/a:1012974728007.
This study examines survival of women with breast cancer using a sample of 1564 cases occurring in 1990 taken from all cases recorded in seven French cancer registries. Age at diagnosis pathological stage (pTNM) and treatment were the criteria selected for the study of the survival. We studied the 5-year observed survival and the relative survival. Tumors pT1 represented 46.7% cases, pT2: 31.6%, pT3 and pT4: 9.2%, and 52% of the tumors had no nodal involvement or metastasis. For cases without surgical treatment the prognosis was poor (observed survival 18.7%, relative survival 25.9%). For women benefiting from neoadjuvant treatment, observed survival rate was 65% after 5 years and relative survival rate 69.1%. For women who were treated first with surgery, the observed survival was 79.5% and the relative survival 86.7%. The survival rate for women under 40 years was slightly lower than for the 40-54-year-old. Using relative survival the youngest group had the worst prognosis and the oldest group the best. In older women, therapeutic strategy might have been more selective which leads to a better prognosis than in the younger age groups treated in a comparable way.
本研究使用从法国七个癌症登记处记录的所有病例中抽取的1990年发生的1564例病例样本，对乳腺癌女性的生存率进行了研究。诊断时的年龄、病理分期（pTNM）和治疗方法是选择用于生存率研究的标准。我们研究了5年观察生存率和相对生存率。pT1期肿瘤占46.7%的病例，pT2期：31.6%，pT3和pT4期：9.2%，52%的肿瘤无淋巴结受累或转移。对于未接受手术治疗的病例，预后较差（观察生存率18.7%，相对生存率25.9%）。对于接受新辅助治疗的女性，5年后观察生存率为65%，相对生存率为69.1%。对于首先接受手术治疗的女性，观察生存率为79.5%，相对生存率为86.7%。40岁以下女性的生存率略低于40-54岁的女性。使用相对生存率，最年轻的组预后最差，最年长的组预后最好。在老年女性中，治疗策略可能更具选择性，这导致其预后比以类似方式治疗的年轻年龄组更好。
